



29 June 2022

Opyl partners with leading patient advocate groups

- NeuroEndocrine Cancer Australia and Pancare Foundation are leading advocates for a large patient community with neuroendocrine cancers and upper GI tract cancers.
- Patient advocacy relationships are important for Opin, Opyl's recruitment platform, in supporting swift clinical trial recruitment by facilitating access to patient communities.
- Patient advocates will provide vital user-experience expertise helping refine and enhance the functionality for the Opin.ai front-end platform.

Melbourne, Australia – Opyl (ASX:OPL) announced today the signing of two important partnerships with patient advocacy organisations –NeuroEndocrine Cancer Australia and Pancare Foundation.

Relationships with patient advocates support the expansion and success of Opin, Opyl's rapidly growing global clinical trial recruitment platform.

Relationships with patient advocates are important in being able to swiftly access patient communities online respectfully, ethically, and appropriately and thus accelerate recruitment to trials via Opin — particularly with rare and aggressive cancers where trials may provide a very significant treatment benefit and in situations where a patient may have a life limiting condition.

A relationship with Opin, ensures that Neuroendocrine Cancer Australia and Pancare Foundation's patient communities are aware of every active, relevant clinical trial and are given every opportunity to participate in those trials. It also ensures that patients can access the newest medicines and diagnostics in development.

Under the agreements, the Opin team will advocate, alongside patient communities, to attract more cancer trials and research investment to Australia, particularly trials for therapies and diagnostics addressing rare and aggressive cancers, as well as apply for joint grants, publish papers, and develop patient co-design opportunities to improve clinical trial design and recruitment service delivery.

"Our approach is to ensure Opin is genuinely of value to patients and to do this we need their input into our technology and service design," said Michelle Gallaher, Opyl CEO. "The Opin clinical trial recruitment team are very excited to work with Neuroendocrine Cancer Australia and Pancare Foundation. I think we have a lot to learn from and offer each other."

Co-design and the vital role patients play in development of health technologies

Creating an opportunity for patients and carers to contribute to the design of health technologies ensures that the solution is fit for purpose and most likely to be adopted and used, thus reducing risk and amplifying value.

Co-design is a concept that ensures the end user is included in the design and development of new technologies or services. Patients and carers are rarely included in the design of new and developing health technologies.



The Board has authorised this announcement for release to the ASX.

-ENDS-

For media and investor enquiries: info@opyl.ai

For clinical trial recruitment enquiries: info@opin.ai

www.opyl.ai

Follow Opyl and Opin on Twitter (@Opylai @Opin_Health), LinkedIn, and Facebook

About Opin

Opin.ai is a global clinical trial recruitment platform and service. With hundreds of patients registering an interest in participating in a clinical trial each day, the platform applies artificial intelligence to match patients in its database to appropriate trials. The Opin team are specialists in social media recruitment strategies and digital advertising, developing bespoke campaigns and smart recruitment strategies for customers using proprietary social media listening technologies and predictive analytics to ensure recruitment success. Opin recruits patients to studies anywhere in the world, and in languages other than English.

About Neuroendocrine Cancer Australia

Neuroendocrine Cancer Australia is the only Australian not-for-profit charity focused on neuroendocrine tumours (NETs). The role of Neuroendocrine Cancer Australia is to: assist and support patients and carers, lobby for new, appropriate treatments and investigations; raise awareness and knowledge of NETs within the medical community and public to support early diagnosis and improved outcomes; and to encourage and support Australian research into neuroendocrine cancers.

Neuroendocrine tumours by their very nature are less common, complicated and disguise themselves behind common symptoms such as irritable bowel syndrome (IBS), asthma and anxiety, which leads to misdiagnosis, poorer outcomes and years of anguish for patients.

About Pancare Foundation

Pancare Foundation are a leading Australian charity committed to inspiring hope, raising awareness, supporting families and funding research for upper gastrointestinal (GI) cancers.

With some of the lowest survival rates out of all the major cancers, we are dedicated to improving outcomes for those affected by upper GI cancers including pancreatic, liver, stomach, biliary and oesophageal cancers.

Pancare provides support for people living with cancer and their families from the point of diagnosis through to treatment and beyond. Pancare also funds world-leading research to increase survival and improve treatment options.